Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;13(1):45-58.
doi: 10.1016/j.jalz.2016.09.014. Epub 2016 Nov 18.

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Sid E O'Bryant  1 , Michelle M Mielke  2 , Robert A Rissman  3 , Simone Lista  4 , Hugo Vanderstichele  5 , Henrik Zetterberg  6 , Piotr Lewczuk  7 , Holly Posner  8 , James Hall  9 , Leigh Johnson  9 , Yiu-Lian Fong  10 , Johan Luthman  11 , Andreas Jeromin  12 , Richard Batrla-Utermann  13 , Alcibiades Villarreal  14 , Gabrielle Britton  14 , Peter J Snyder  15 , Kim Henriksen  16 , Paula Grammas  17 , Veer Gupta  18 , Ralph Martins  18 , Harald Hampel  4 ; Biofluid Based Biomarker Professional Interest Area
Affiliations

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

Sid E O'Bryant et al. Alzheimers Dement. 2017 Jan.

Abstract

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.

Keywords: Alzheimer's disease; Biomarker; Blood; Cerebrospinal fluid; Context of use; Diagnosis; Imaging.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current Model of Biomarker Development
Figure 2
Figure 2
Public-Private Partnership Model for Moving from Biomarker Discovery to Clinical Use
Figure 3
Figure 3
Potential Landscape of Diagnostic Process Biomarkers in Alzheimer’s Disease
Figure 4
Figure 4
Potential Biomarker COUs in Alzheimer’s Disease Clinical Trial Designs
See this image and copyright information in PMC

References

    1. Snyder HM, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2014;10(1):109–114. - PMC - PubMed
    1. Henriksen K, et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimer's and Dementia. 2014;10(1):115–131. - PMC - PubMed
    1. O'Bryant SE. Introduction to special issue on advances in blood-based biomarkers of Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2016;3:1–3. - PMC - PubMed
    1. Lista S, F F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol. 2013;101–102:1–17. - PubMed
    1. O'Bryant SE, E M, Johnson LA, Hall JA, Villarreal AE, Britton GB, Quiceno M, Cullum CM, Graff-Radford NR. A Blood Screening Test for Alzheimer's Disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2016;3:83–90. - PMC - PubMed

Publication types